Li Fu
Impact in
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 1%
- Cancer Cells and Metastasis
Papers in
-
- Epigenetics and DNA Methylation 34
- Cancer-related gene regulation 34
- RNA modifications and cancer 32
- Wnt/β-catenin signaling in development and cancer 13
-
- Cancer-related molecular mechanisms research 19
- MicroRNA in disease regulation 16
- Cancer, Hypoxia, and Metabolism 12
- Co-authors
- Xin‐Yuan Guan (55 shared papers)Tuxiong Huang (10 shared papers)Ehud Lavi (13 shared papers)Canhua Huang (3 shared papers)Zhao Huang (2 shared papers)Dan Xie (15 shared papers)Na Xie (2 shared papers)Guobo Shen (1 shared paper)
- Journals
- Cancer Research (10 papers)Frontiers in Oncology (6 papers)PLoS ONE (6 papers)Oncotarget (6 papers)Oncogene (5 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Li Fu
233 papers receiving 8.7k citations
Li Fu's Hit Papers
Peers
Comparison fields: 5 of 149
- Cancer Research 2.4k
- Oncology 2.1k
- Molecular Biology 5.2k
- Immunology 1.4k
- Virology 182
Countries citing papers authored by Li Fu
This map shows the geographic impact of Li Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Fu more than expected).
Fields of papers citing papers by Li Fu
This network shows the impact of papers produced by Li Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Fu. The network helps show where Li Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Li Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 242 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Neoantigens: promising targets for cancer therapy Hit paper breakdown → | 2023 | 536 |
| 2 | 2013 | 394 | |
| 3 | 2018 | 205 | |
| 4 | CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons. | 1997 | 201 |
| 5 | 2019 | 186 | |
| 6 | 2009 | 180 | |
| 7 | 2012 | 169 | |
| 8 | 2019 | 166 | |
| 9 | Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management Hit paper breakdown → | 2022 | 152 |
| 10 | 2021 | 142 | |
| 11 | 2009 | 134 | |
| 12 | 2008 | 132 | |
| 13 | 2008 | 131 | |
| 14 | 2013 | 128 | |
| 15 | 2007 | 125 | |
| 16 | 2004 | 120 | |
| 17 | 2017 | 108 | |
| 18 | 2011 | 107 | |
| 19 | 1998 | 99 | |
| 20 | 2018 | 98 |
About Li Fu
Li Fu is a scholar working on Molecular Biology, Cancer Research, Oncology, Immunology and Surgery, having authored 242 papers that have together received 8.8k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (34 papers), Cancer-related gene regulation (34 papers), RNA modifications and cancer (32 papers), Cancer-related molecular mechanisms research (19 papers), MicroRNA in disease regulation (16 papers), Cancer Cells and Metastasis (15 papers), Wnt/β-catenin signaling in development and cancer (13 papers) and Cancer, Hypoxia, and Metabolism (12 papers). The work is most often cited by research in Cancer Research (2.4k citations), Oncology (2.1k citations), Molecular Biology (5.2k citations), Immunology (1.4k citations) and Virology (182 citations). Li Fu has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Xin‐Yuan Guan, Tuxiong Huang, Ehud Lavi, Canhua Huang, Zhao Huang, Dan Xie, Na Xie, Guobo Shen, Wei Gao and Leilei Chen. Their work appears in journals such as Cancer Research, Frontiers in Oncology, PLoS ONE, Oncotarget and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.